Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

NCT02079870 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication semaglutide affects appetite, food intake, blood sugar, and fat metabolism in people with obesity, compared to a placebo.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 30 people

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2014-03 · est. completion 2015-01

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT02079870 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects compared with placebo.

Treatments tested

semaglutide Drug

Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
placebo Drug

Solution for subcutaneous (s.c. - under the skin) injection

Main thing measured	Ad libitum energy intake during a lunch meal (following a standardised breakfast meal)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02079870 ↗